Sometimes, it makes sense to skip insurance and instead take advantage of a health savings account or flexible savings ...

Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...

A global trial finds Wegovy and Ozempic significantly improve liver health in patients and treats those with advanced fatty ...

Study participants were randomly assigned 2:1 to receive oral semaglutide 25mg (n=205) or placebo (n=102), as an adjunct to lifestyle intervention. The coprimary endpoints were the relative change in ...

The active ingredient in the popular weight loss drug Wegovy may help treat a type of fatty liver disease, according to a new study published Wednesday.

A decision is expected in the fourth quarter of 2025.

The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

Novo Nordisk (NVO) stock in focus as oral Wegovy is accepted for FDA review for chronic weight management. Read more here.

Semaglutide - the active ingredient in medications like Ozempic and WeGovy - is only FDA approved for Type-2 diabetes, but ...

Ozempic’s popularity for weight loss is growing, and according to a 2024 survey from KFF, about two in five adults in the US ...

For patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, semaglutide is associated with ...